IT-09 PHASE I STUDY OF SAFETY, TOLERABILITY AND IMMUNOLOGIC EFFECTS OF A SURVIVIN PEPTIDE MIMIC VACCINE (SurVaxM) IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA

BACKGROUND: Survivin is an inhibitor of apoptosis protein (IAP) that is highly expressed in malignant gliomas and other cancers. Induction of cytotoxic immunity against survivin is an attractive antitumor strategy. Preclinical studies demonstrated the ability of a KLH-conjugated survivin peptide mim...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fenstermaker, Robert, Mechtler, Laszlo, Qiu, Jingxin, Mogensen, Kathleen, Ahluwalia, Manmeet, Adjei, Alex, Lee, Kelvin, Ciesielski, Michael
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2014
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218258/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou258.7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares